Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Still waiting for my HOTH shares. Had planned to buy cases of Guinness and some wees with it for this weekend and call it a hit from the clueless market makers that love my trades. I guess I'd have to move that to next week.
Just want $1....or $320 gain for each $680 times all my shares. The clueless MMs owes me that now. Roughly and at most, a week to cash!!!
AIKI gonna spike to $3.00-5.00 ,1000%%%%%%%%%%%%%%%%%%%%,waiting here
Lol...over $11k today across the five stocks I battle with these fools. Best news, they hold other down for me to take profits and add. It's been a pleasure knowing you IDIOTS. Please keep this here for now. Was loading the $0.64s like crazy yesterday and doing $0.66s today. Amazing whether these idiots ever made any money for their firms as they follow me to pathetic loses
You are smar8than the DUMB MMs that sold it to you. It's all set for that $1-$1.40 run to flush current shorts and DUMB MM positions before next share sale. That's the game. GUARANTEED
Anthony I loaded .65 today give me that 1$ run
Anthony Hayes is a dirt bag!! Wow!!! Look at all those dumps !! .4 here is comes
nice double bottom here :)
Shelf offering 100 million OMG!!! Watch the massive dip and then the biggest pump here ever !!!
Shel offering is always followed with a huge pump!!
Load up the dip!!!
AIKI...72...Consolidation Breakout setting up here...imo...we shall see...
Chart...http://schrts.co/IUgXVxJt
I feel I'm being played again. The PR reads:
"The Company will update stockholders on the date of distribution as soon as possible. Stockholders should note that the record date for the distribution has not changed and individuals who were stockholders at 5:00 p.m. on April 30, 2020 will still be receiving the distribution. No further action by shareholders is necessary to receive the distribution. We regret the delay and frustration this may cause the Company's stockholders."
Does that mean new investors cannot draw on that 70,000,000 dividend pool as happened the last time; ie THE DATE OF RECORD FOR THIS PARTICULAR BATCH WILL NOT BE EXTENDED. Isn't that how 70 AIKI turned into 500 AIKI in the previous fiasco? Note they did not even reconfirm that
controversial 1-500 ratio.
Who are they kidding? System applications are already in place for digital stock transfer within 24 hours to all online brokers which probably accounts for all our accounts. SOMETHING'S FISHEY HERE. FOOL ME THREE TIMES,. SHAME ON ME.
Bought Some of those;)
Anthony Hayes is selling a shit load of shares at .71 - .72 what a turd !!!
Don't!!! This message is for the DUMB MARKET MAKERS:
When I was 4 years old, I liked being naked. I hated wearing clothes. My grandmother was staying with us and did most of the cooking. I likes going to the kitchen and watching her cook. And I did so.....NAKED. Now, here's the message:
My grandmother will tell at me.....
"Odure, Odure, please get out of the kitchen or fire from the stove will burn your penis."
Haaaahaaahaaa!!!
TRASH SELL THIS SHOT AND GO TO OTHER PLAYS !!!
ANTHIBY HAYES DUMP ALREADY!!! BIG BID WAITING AT .5
Dilution at these level for the massive dump shortly after !! Back down to .4 Anthony Hayes did this same pattern when this traded as SPEX a few months back.
The pump was .87 then shot down to .44
Lmao!! This turd back down .6 watch Anthony Hayes is a scammer !!! Give up sell !!
Back down this turf goes !! Erase 1$ from this turf is not happening !! .85 was the highest this will go for a LONG !!!!!! Time
I told ya!! Anthony Hayes a pumpster !! Now this takes the drop to .4 again!! Familiar pattern to when this traded under SPEX
Some private message from some dumb MARKET MAKER saying "talk shit now!" And I just did. More so, the shit I talked yesterday netted me $2600. And it is now fully redeployed here for a crawling DOUBLE. APPLAUD ME clueless MMs!!!
Yes it could, I've seen it multiple times run that high, and even higher to $15.
Our drug portfolio focuses on the treatment of three cancers, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL).
Our pancreatic cancer drug was developed at University of Texas at Austin. The new drug, “DHA-dFdC”, is a new compound that holds promising indications of becoming the next generation of chemotherapy treatment for advanced pancreatic cancer. DHA-dFdC also overcomes tumor cell resistance to current chemotherapeutic drugs and is well tolerated in preclinical toxicity tests. Preclinical studies have also indicated that the drug: Inhibits pancreatic cancer cell growth (up to 100,000-fold more potent that gemcitabine, a current standard therapy), Has documented efficacy against pancreatic tumors in a clinically relevant transgenic mouse model, Overcomes tumor cell resistance to current chemotherapeutic drugs, Is well tolerated in preclinical toxicity test, Has demonstrated activities against other cancers (e.g. leukemia, lung, melanoma)
Our AML drug, developed at Wake Forest Univeristy, is a next generation targeted therapeutic designed to overcome multiple resistance mechanisms observed with the current standard of care. Our pancreatic treatment has shown positive preclinical results for inhibiting pancreatic tumor growth in clinically relevant transgenic mouse models. The drug has also demonstrated the potential to overcome tumor cell resistance to current chemotherapeutic drugs.
Combined, AIkido Pharma Inc. ’s platform offers a robust drug pipeline focused on the development and commercialization of drugs to treat unmet medical needs in oncology.
https://ir.aikidopharma.com/news-releases/ It needs to continue up from .85 that hit today.
AIKI could run $5.00- $10.00 gonna hold here baby
AIKI~~CRAZY HUGE NEWSSS!!Cogia Biotech LTD is a GERMAN CO,,
May 06 2020 - 01:30PM
AIkido Pharma Executes Artificial Intelligence and Machine Learning Research Agreement with Cogia Biotech LTD
May 06 2020 - 01:30PM
PR Newswire (US) Print
NEW YORK, May 6, 2020 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) today announced execution of an Artificial Intelligence (AI), and Machine Learning (ML) research agreement with Cogia Biotech LTD ("Cogia") (www.cogia.de) to accelerate the Company's pancreatic cancer genetic marker research. Cogia is a Big-data, AI, and ML software company committed to using powerful AI engines and algorithms to develop compelling outcomes in drug development. Cogia provides state-of-the-art digital information and discovery tools to subject-matter experts and scientists working in genetics and cancer research, to advance drug development. Cogia's existing clients include many international companies, including international pharmaceutical companies.
(PRNewsfoto/AIkido Pharma Incorporated)
Cogia will augment the Company's efforts of using machine learning to find genetic markers that could lead to pancreatic cancer. As with many cancers, early detection is vital, but in pancreatic cancer, surgical intervention is currently the only effective treatment for the extension of life. Pancreatic cancer is relatively rare; however, it is the third leading cause of cancer deaths in the United States. The disease is often asymptomatic, making early detection and treatment difficult or even impossible. Only 20% of individuals are diagnosed with pancreatic cancer early enough to be surgical candidates. Reliable markers for early detection will expand the number of patients who are eligible for life-extending surgery.
Andreas Typaldos, Executive Chairman of Cogia Biotech, expressed his excitement about the research agreement with AIkido. "Even during the preparatory work leading up to this strategic agreement with AIkido, one could see the promise of compelling outcomes in early and better detection of pancreatic cancer and possibility for novel and more effective therapeutics using state-of-the-art technologies like AI and ML. The very earliest project-design work sessions between Cogia Biotech AI/ML data scientists, bio-informatics engineers, and cancer research scientists, on one hand, and AIkido and University of Texas Southwestern Medical Center research scientists, on the other, clearly pointed to how compelling and appropriate is the vision of Anthony Hayes for having AIkido use of these breakthrough biotech technologies in disease detection and drug development. We are excited and honored to be part of Anthony's plan and effort."
Anthony Hayes, CEO of AIkido stated, "We have completed several significant capital raises and are now putting that capital to work with the aim of achieving asymmetric rewards for our shareholders. As part of our goal to increase our use of AI and ML in drug development, our new research agreement with Cogia augments our pancreatic cancer research project with the University of Texas Southwestern Medical Center. Cogia has significant depth and skill, as demonstrated by their notable client base. We believe that Cogia can help us use machine learning to develop panels of markers to rapidly identify patients who have initiated early events in pancreatic cancer. Moreover, it is the goal of the machine learning protocols to identify which individuals are at risk for slow or rapid progression of the disease and catalyze the development of better early detection methods. It is our objective that the machine learning approach will help identify drugs best suited for potentially lifesaving individual patient treatment. We are proud to partner with Cogia on this project."
About AIkido
AIkido was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics. The Company's platform consists of patented technology from leading universities and researchers and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and Wake Forest University. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In addition, we are constantly seeking to grow our pipeline to treat unmet medical needs in oncology
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.
Contact:
Investor Relations:
Hayden IR
Brett Maas, Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com
AIkido:
Phone: 212-745-1373
Email: investorrelations@AIkido.com
www.AIkido.com
Cision View original content to download multimedia:www.prnewswire.com/news-releases/aikido-pharma-executes-artificial-intelligence-and-machine-learning-research-agreement-with-cogia-biotech-ltd-301054142.html
SOURCE AIkido Pharma Inc.
GERMAN CO WEBSITE~~HUGEEEEE
https://www.cogia.de/en/
Strong green close today sets us for nice run next week in my opinion.
$AIKI
no more offerings from $AIKI for the foreseeable future. Still bullish.
$AIKI AIkido Pharma Executes Artificial Intelligence and Machine Learning Research Agreement https://conta.cc/3fp3jwB
ANOTHER PUMP AND DUMP FOR MR HAYES!!! Tomorrow .5
Now this trash will shoot down to .5 GL BAGHOLDERS !!!
LMAO!! Who got caught by the infamous Anthony Hayes ? Everyone here waiting for 1$ lmao! Not happening !!
$AIKI awesome news! With the history of their crazy spikes, this is going to be fun to watch. I'm all in!
Aiki my freaking $5 dollars pps coming,is a weeeeeeeeeeeee bank
Followers
|
156
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
8287
|
Created
|
12/30/04
|
Type
|
Free
|
Moderators |
Kucera Paper Lipid Nucleoside Conjugates for the Treatment of Cancer
Kucers & Pardee Paper Improving Nucleoside Analogs via Lipid Conjugation
The Phospholipid Gemcitabine Conjugate, KPC34, is a Novel Treatment for Leukemia
Short-term Toxicity Study of DHA-dFdC
AIkido Pharma Inc. seeks to enhance shareholder value not only through exceptional business performance and practices,
but also through responsible and effective communication with its shareholders. The latest company information relevant to the individual
and institutional investor includes stock price and history, upcoming events and presentations and financial documents.
AIkido Pharma Inc. is traded on the Nasdaq under the ticker symbol AIKI.
AIkido Pharma Inc. is a biotechnology development company with a diverse portfolio of early stage small-molecule anti-cancer therapeutics.
The Spherix platform contains patented technology from leading universities and researchers and we seek to develop
our innovative drugs through strong partnership with world renowned institutions, such as The University of Texas and Wake Forest University.
Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL).
Our pancreatic treatment has shown positive preclinical results for inhibiting pancreatic tumor growth in clinically relevant transgenic mouse models.
The drug has also demonstrated the potential to overcome tumor cell resistance to current chemotherapeutic drugs.
Our AML drug is a next generation targeted therapeutic designed to overcome multiple resistance mechanisms observed with the current standard of care.
In addition, we are constantly seeking to grow our pipe to treat unmet medical needs in oncology.
https://ir.aikidopharma.com/stock-information/
$AIKI Spherix Incorporated, a biotechnology company,focuses on developing small-molecule anti-cancer therapeutics.
Its pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia.
The company's platform consists of patented technology from leading universities and researchers and in the process of developing an
innovative therapeutic drug platform through partnerships with world renowned educational institutions, including The University of Texas at
Austin and Wake Forest University.
It has a scientific research agreement with The University of Texas Southwestern Medical Center to use machine learning to find genetic
markers in people that indicate an increased risk of developing pancreatic cancer.
Spherix Incorporated was founded in 1967 and is based in New York, New York.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |